Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPIXNASDAQ:FWPNASDAQ:LIXTNASDAQ:RGLSNASDAQ:SNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPIXCumberland Pharmaceuticals$3.15-7.6%$4.77$1.04▼$7.25$47.13M-0.39870,485 shs120,657 shsFWPForward Pharma A/S$1.95$2.17$1.50▼$6.48$13.83M1.387,484 shsN/ALIXTLixte Biotechnology$2.63+30.1%$1.27$0.64▼$4.25$7.60M0.31648,227 shs64.13 million shsRGLSRegulus Therapeutics$8.16$7.83$0.83▼$8.35$564.92M0.35985,580 shsN/ASNGXSoligenix$1.20-4.8%$1.78$1.20▼$14.83$3.92M1.87962,295 shs291,008 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPIXCumberland Pharmaceuticals0.00%+21.15%-43.04%-25.53%+105.88%FWPForward Pharma A/S0.00%0.00%0.00%0.00%0.00%LIXTLixte Biotechnology0.00%+267.90%+89.14%+117.27%+13.32%RGLSRegulus Therapeutics0.00%0.00%+2.64%+384.27%+353.33%SNGXSoligenix0.00%-11.76%-36.84%-34.78%-46.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPIXCumberland Pharmaceuticals0.584 of 5 stars0.03.00.00.02.11.70.0FWPForward Pharma A/SN/AN/AN/AN/AN/AN/AN/AN/ALIXTLixte Biotechnology0.9179 of 5 stars0.05.00.00.02.30.80.0RGLSRegulus Therapeutics1.6124 of 5 stars2.15.00.00.00.03.30.0SNGXSoligenix1.5171 of 5 stars0.05.00.00.02.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPIXCumberland Pharmaceuticals 0.00N/AN/AN/AFWPForward Pharma A/S 0.00N/AN/AN/ALIXTLixte Biotechnology 0.00N/AN/AN/ARGLSRegulus Therapeutics 2.29Hold$8.504.17% UpsideSNGXSoligenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SNGX, FWP, CPIX, RGLS, and LIXT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$9.004/30/2025RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/30/2025RGLSRegulus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$7.004/30/2025RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$28.00 ➝ $11.004/30/2025RGLSRegulus TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $7.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPIXCumberland Pharmaceuticals$37.87M1.24$0.26 per share12.25$1.61 per share1.96FWPForward Pharma A/SN/AN/AN/AN/A$10.09 per shareN/ALIXTLixte BiotechnologyN/AN/AN/AN/A($1.19) per shareN/ARGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/ASNGXSoligenix$120K32.60N/AN/A$1.64 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPIXCumberland Pharmaceuticals-$6.48M-$0.25N/A∞N/A-7.98%6.92%2.33%8/5/2025 (Estimated)FWPForward Pharma A/S-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALIXTLixte Biotechnology-$3.59M-$1.45N/A∞N/AN/AN/A-189.35%8/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)SNGXSoligenix-$8.27M-$4.29N/AN/AN/AN/A-223.89%-103.50%8/8/2025 (Estimated)Latest SNGX, FWP, CPIX, RGLS, and LIXT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025LIXTLixte BiotechnologyN/A-$0.29N/A-$0.29N/AN/A5/9/2025Q1 2025SNGXSoligenix-$0.67-$1.06-$0.39-$1.06N/AN/A5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/A5/6/2025Q1 2025CPIXCumberland PharmaceuticalsN/A$0.15N/A$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/AFWPForward Pharma A/SN/AN/AN/AN/AN/ALIXTLixte BiotechnologyN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASNGXSoligenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPIXCumberland Pharmaceuticals0.181.251.09FWPForward Pharma A/SN/A18.43N/ALIXTLixte BiotechnologyN/A4.264.26RGLSRegulus TherapeuticsN/A16.3116.31SNGXSoligenixN/A1.851.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPIXCumberland Pharmaceuticals15.51%FWPForward Pharma A/S12.57%LIXTLixte Biotechnology5.10%RGLSRegulus Therapeutics92.38%SNGXSoligenix3.60%Insider OwnershipCompanyInsider OwnershipCPIXCumberland Pharmaceuticals44.85%FWPForward Pharma A/S71.47%LIXTLixte Biotechnology14.80%RGLSRegulus Therapeutics4.35%SNGXSoligenix3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPIXCumberland Pharmaceuticals8014.96 million8.25 millionOptionableFWPForward Pharma A/S47.09 million2.02 millionNot OptionableLIXTLixte Biotechnology42.68 million2.29 millionNot OptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableSNGXSoligenix203.26 million3.16 millionNot OptionableSNGX, FWP, CPIX, RGLS, and LIXT HeadlinesRecent News About These CompaniesSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - Seeking AlphaJuly 3 at 4:33 PM | seekingalpha.comSoligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma SolutionsJuly 1, 2025 | prnewswire.comSoligenix Approves 2025 Equity Incentive Plan at MeetingJune 20, 2025 | tipranks.comSoligenix (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s DiseaseJune 17, 2025 | theglobeandmail.comSoligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | finance.yahoo.comSoligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical TrialsJune 6, 2025 | globenewswire.comSoligenix’s (NASDAQ: SNGX) HyBryte(TM) Delivers Strong Results in Rare Cancer TrialMay 24, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) Reports Q1 Milestones, Financial ResultsMay 20, 2025 | theglobeandmail.comSNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…May 13, 2025 | finance.yahoo.comSOLIGENIX, INC.: Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deSoligenix Announces Recent Accomplishments And First Quarter 2025 Financial ResultsMay 9, 2025 | prnewswire.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comSoligenix (NASDAQ: SNGX) CEO Highlights Pipeline and Strategy in BioMedWire Podcast EpisodeMay 7, 2025 | theglobeandmail.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Christopher Schaber, CEO of Soligenix Inc.May 7, 2025 | finance.yahoo.comSoligenix $SNGX HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 30, 2025 | msn.comSolgenix shares rise on positive skin cancer treatment resultsApril 24, 2025 | investing.comFireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.April 24, 2025 | msn.comEQS-News: Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA FundingApril 24, 2025 | markets.businessinsider.comSNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…April 14, 2025 | msn.comPositive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 WeeksApril 14, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNGX, FWP, CPIX, RGLS, and LIXT Company DescriptionsCumberland Pharmaceuticals NASDAQ:CPIX$3.15 -0.26 (-7.62%) As of 07/3/2025 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Forward Pharma A/S NASDAQ:FWPForward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing FP187 proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. Forward Pharma A/S was incorporated in 2005 and is headquartered in Copenhagen, Denmark.Lixte Biotechnology NASDAQ:LIXT$2.63 +0.61 (+30.15%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$2.38 -0.25 (-9.66%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Regulus Therapeutics NASDAQ:RGLS$8.16 0.00 (0.00%) As of 06/25/2025Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Soligenix NASDAQ:SNGX$1.20 -0.06 (-4.76%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.